Showing 891-900 of 4263 results for "".
Seborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Rosacea Treatment Options and Strategies
https://reachmd.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.GEP Testing in Surgical Oncology
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-in-surgical-oncology/35601/Surgical oncologist J. Michael Guenther, MD, discusses how to use gene expression profile (GEP) testing for managing melanoma patients.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseCanadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.Urticaria: Dr. Hawkes
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/urticaria-dr-hawkes/32690/Jason Hawkes, MD, talks about how to manage and approach chronic spontaneous urticaria patients, as well as novel therapeutic options, all of which he covered in "Urticaria Update 2025" at Maui Derm 2025.Skin of Color Session: Dr. Taylor
https://reachmd.com/programs/practical-dermatology/skin-of-color-session-dr-taylor/32674/Susan Taylor, MD, summarizes her presentation during the "Skin of Color Session" at Maui Derm 2025, including a discussion of photoprotection for patients with vitiligo, hyperpigmentation, and melasma.Growth Potential of the Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/growth-potential-of-the-aesthetic-market/29746/Merz Aesthetics President, North America, Patrick Urban discusses why he expects demand for aesthetic treatments to continue increasing and how to capitalize on it.